logo-loader
ImmuPharma PLC

Appointment of Nominated Adviser

/**/ h1{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:72.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h2{margin:0cm;margin-bottom:.0001pt;text-align:center;text-autospace:none;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h3{margin:0cm;margin-bottom:.0001pt;text-align:center;text-autospace:none;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:bold;text-decoration:underline;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: #954F72 } .br{size:595.3pt 841.9pt;margin:72.0pt 46.3pt 53.95pt 90.0pt;}div.br{}p.di{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold}span.dg{font-family:"Calibri","sans-serif"; color:black}span.de{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black}p.dj{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold; text-align: center}span.dd{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}p.dk{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; text-align: center}p.dl{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";background:white}p.dm{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";text-align:justify;background:white} span.cz{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}p.dn{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold; text-align: justify}span.cw{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.do{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-div: italic; text-align: justify}table.dp{width:606.25pt;margin-left:-10.8pt;border-collapse:collapse}td.by{width:595.45pt;padding:0cm 5.4pt 0cm 5.4pt}p.dq{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";text-align:justify}table.dr{width:18.0cm;border-collapse:collapse}td.cs{width:294.0pt;padding:0cm 5.4pt 0cm 5.4pt}p.ds{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: justify} td.cq{width:194.7pt;padding:0cm 5.4pt 0cm 5.4pt}span.cr{font-size:11.0pt; font-family:"Calibri","sans-serif"}span.cp{font-size: 11.0pt;font-family:"Calibri","sans-serif"}p.dt{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";text-align:justify; text-autospace:ideograph-numeric ideograph-other}span.cn{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:black}p.du{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; punctuation-wrap: hanging; text-align: justify; text-autospace: ideograph-numeric ideograph-other}span.dv{color:blue;font-size:11.0pt;font-family:"Calibri","sans-serif"; color:windowtext;text-decoration:none}p.dw{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";margin-right:-5.4pt;text-align:justify}td.cd{width:449.9pt;padding:0cm 5.4pt 0cm 5.4pt}span.cj{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:#333333;background:white} span.ci{font-size:11.0pt; font-family:"Calibri","sans-serif";color:#333333;background:white}span.cg{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:#333333}span.ch{background:white}span.cf{font-size:11.0pt;font-family:"Calibri","sans-serif";background:white}p.dx{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold}td.cc{width:38.8pt;padding:0cm 5.4pt 0cm 5.4pt}td.cb{width:150.5pt;padding:0cm 5.4pt 0cm 5.4pt}td.ca{border:none;padding:0cm 0cm 0cm 0cm}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";}td.bv{width:456.8pt;padding:0cm 5.4pt 0cm 5.4pt} p.dy{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:-157.35pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;text-align:justify}span.bx{font-family:"Calibri","sans-serif"}td.bu{border:none}span.dz{color:blue;text-decoration:underline;font-family: "Calibri","sans-serif"; text-decoration: none} /**/
RNS Number : 5484K
Immupharma PLC
17 December 2018
 

 

                                                                                                                                                                 17 December 2018

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

APPOINTMENT OF NOMINATED ADVISOR

 

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company is pleased to announce the appointment of SPARK Advisory Partners Limited ("SPARK") as the Company's Nominated Advisor ("NOMAD"), with immediate effect.

 

Commenting on the appointment, ImmuPharma's Chairman, Tim McCarthy, said:

 

"I am delighted to announce the appointment of SPARK as the Company's NOMAD. We look forward to working with the team going forward, alongside our joint brokers, Stanford Capital Partners and SI Capital."

 

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")

 

 

For further information please contact:

 

ImmuPharma plc (www.immupharma.com)

+ 44 (0) 207 152 4080

Tim McCarthy, Chairman

 

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

Vassil Kirtchev

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0) 203 368 8974

 

 

 

+44 (0) 203 815 8880

 

 

+44 (0) 1483 413500

 

 

 

About SPARK Advisory Partners Limited

 

SPARK Advisory Partners was established in January 2012 by its founding partners to provide product independent corporate finance advice to mid-market companies, owner managers and shareholders.
SPARK is owned by its partners who have worked together for many years. The team has a broad cross section of skills and transaction experience, encompassing M&A, private equity, public capital raisings and debt advisory services. For more information go to: www.sparkadvisorypartners.com


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
APPBBBDDCBBBGIS

Quick facts: ImmuPharma PLC

Price: £0.10

Market: AIM
Market Cap: £16.19 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Successful AstraZeneca lupus study bodes well for ImmuPharma's Lupuzor - analyst

Dr Navid Malik, Head of Life Sciences Research, tells Proactive London's Andrew Scott the recent positive update for AstraZeneca's lupus drug Anifrolumab is not only positive for the Lupus field but also serves as a reminder that ImmuPharma PLC’s (LON:IMM) Lupuzor drug could represent a highly...

1 week, 4 days ago